Zoetis has announced that Vetscan Imagyst, its multi-purpose diagnostic tool, is getting 'AI Masses', a new capability which uses best-in-class AI to analyse potentially neoplastic cells in lymph node and subcutaneous lesions.

The company says AI Masses will allow veterinary professionals to analyse lesions suggestive of cancer in-clinic and with a fast turnaround.

The AI technology, which has been trained by human clinical pathologists, should enable individualised treatment outcomes earlier for more cases.

Zoetis says AI Masses only needs a single round of sample preparation and the results can, at additional cost, be supplemented with an expert review from a network of specialists through Zoetis’ Virtual Laboratory.

Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening.

"Our research shows that up to 75% of pet owners find abnormal results highly stressful.1

"AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”

Pre-orders will be announced for US customers in Q2 2025.

VetSurgeon.org understands AI Masses will be coming to the UK some time in 2025.

https://www.zoetisdiagnostics.com 

Reference

  1. StayWell Health Screening Report prepared for Zoetis, 2022

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.